However, when treated with the Reparixin (inhibitor of IL‐8 receptors CXCR1 and CXCR2), the migration of ovarian cancer cells decreased compared with the control group no matter whether treated or not treated with the IL‐8. This evidence concerns the gene CXCR1 and ovarian carcinoma.